|1.||Perou, Charles M: 69 articles (07/2015 - 07/2003)|
|2.||Luszczki, Jarogniew J: 33 articles (09/2015 - 05/2003)|
|3.||Reis-Filho, Jorge S: 26 articles (05/2015 - 05/2004)|
|4.||Børresen-Dale, Anne-Lise: 25 articles (04/2015 - 07/2003)|
|5.||Czuczwar, Stanislaw J: 24 articles (12/2011 - 06/2002)|
|6.||Serruys, Patrick W: 23 articles (12/2015 - 06/2002)|
|7.||Ellis, Ian O: 23 articles (09/2015 - 06/2004)|
|8.||Troester, Melissa A: 22 articles (12/2015 - 06/2004)|
|9.||Jukema, J Wouter: 22 articles (08/2012 - 01/2002)|
|10.||Czuczwar, Stanisław J: 21 articles (06/2014 - 08/2002)|
04/01/1998 - "A marked improvement could be observed for most of the patients treated with phenobarbitone in terms of reduction of seizure frequency although complete seizure control was achieved in only a few."
12/01/2011 - "Our findings demonstrate pronounced cell death in several important regions of the rat limbic system following neonatal administration of phenobarbital, the first-line treatment for neonatal seizures in humans. "
08/01/1977 - "Complete protection against IPS-induced seizures was observed for a period of 6 h after acute phenobarbital administration during which the mean plasma phenobarbital concentrations were between 16.2 +/- 0.91 and 13.6 +/- 1.0 microgram/lm. "
03/01/2015 - "This compound was effective in delaying onset of PTZ-evoked seizures at the dose of 5mg/kg in kindled animals and significantly reduced oxidative stress better than standard drug phenobarbital (PB). "
11/01/2014 - "Available data suggests that phenobarbital is as effective as other first-line drugs for treating tonic-clonic seizures, but side effect reports differ widely between high and low-income settings. "
|2.||Pathologic Constriction (Stenosis)
12/01/2015 - "Minimal luminal diameter or percent stenosis improved significantly from baseline after 2 BU runs, but no further gain was seen between 2 and 4 BU runs (P > .05). "
09/01/2013 - "Using the CARD technique, needle knife dissection and APC, individually or in combination, luminal patency of occlusive esophageal strictures can be accomplished safely with good results."
06/01/2010 - "Using DSA as the "gold standard," sensitivities and specificities for detecting significant arterial stenoses (>/=50% luminal narrowing) with first-pass WB-MRA, SS-MRA, and combined first-pass and SS-MRA were calculated. "
10/15/2008 - "We compared both quantitative coronary angiography (QCA) and MSCT to the gold standard for a significant stenosis-minimum luminal area (MLA) by intravascular ultrasound (IVUS)-in 51 patients (64 +/- 10 years old, 19 men) with 69 angiographically ambiguous, nonleft main lesions. "
03/21/2006 - "In coronary arteries with <50% stenosis, there were no temporal changes in luminal and plaque dimensions measured by quantitative coronary angiography or IVUS; however, a significant reduction in abnormal strain pattern was detected on palpography (density high strain spots/cm: 1.6 +/- 1.5 vs. 1.2 +/- 1.4, p = 0.0123. "
04/01/2013 - "To the best of our knowledge, we have shown for the first time that MMP-2(-) in stromal fibroblasts might indicate poor survivors in the group of patients with grade 3 tumors and that the cumulative effect of both above-mentioned parameters might be helpful in selecting the high-risk individuals from the group of patients with luminal B subtype/HER2(+)/triple negative phenotype identified according to St Gallen recommendations."
01/01/2013 - "Luminal A tumors are the most frequent subtype in MBC, with a better outcome than Luminal B subtype. "
10/01/2012 - "'Luminal A' tumors presented with the best outcome parameters but the effect weakened at longer follow-up. "
02/01/2012 - "Patients with luminal A tumors had the best prognosis, with improved disease-free survival (log-rank, P = 0.033) and overall survival (P = 0.006) compared with the other three tumor subtypes. "
01/01/2012 - "Among 232 luminal A and 49 CBP cancers associated with evaluable TDLUs, CBP tumors were associated with significantly greater average number of acini per TDLU (odds ratio (OR) = 3.36, 95% confidence interval (CI) = 1.36 to 8.32, P = 0.009) and larger average TDLU diameter (OR = 2.49, 95% CI = 1.08 to 5.74, P = 0.03; comparing highest to lowest group, adjusted for age and study site). "
|4.||Crohn Disease (Crohn's Disease)
08/01/2014 - "Dietary therapy involving PEN with an exclusion diet seems to lead to high remission rates in early mild-to-moderate luminal Crohn's disease in children and young adults."
05/16/2009 - "The authors conclude that the three above-mentioned agents are effective in luminal Crohn's disease. "
05/01/2013 - "Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease."
09/01/2009 - "Eligible patients had active steroid-dependent luminal Crohn's disease and received IFX (5 mg/kg at weeks 0, 2, and 6 for induction and then scheduled q8 week for remission maintenance). "
01/01/1997 - "Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: colonic luminal pH in normal subjects and patients with Crohn's disease."
01/01/2002 - "Low doses of phenobarbital were very effective against epilepsy. "
09/01/2006 - "High-dose phenobarbital therapy is effective for refractory epilepsy in patients complicated by respiratory distress. "
12/01/2012 - "Phenobarbital is an effective treatment for epilepsy but concerns remain over its potential neurocognitive toxicity. "
01/01/1987 - "Seventy-five children with different nutritional status, who were receiving phenobarbitone for treatment of various seizure disorders, were monitored for their plasma steady state level, therapeutic efficacy and toxicity. "
05/23/2006 - "[Evaluation of the efficacy of phenobarbital in treatment of epilepsy in rural areas: study of 2455 patients in rural China]."
|3.||Valproic Acid (Valproate, Semisodium)
|5.||Anticonvulsants (Antiepileptic Drugs)
|4.||Drug Therapy (Chemotherapy)